ARWR Arrowhead Pharmaceuticals reports topline results from phase 3 shasta-3 and shasta-4 studies of plozasiran in patients with severe hype
ARWR Arrowhead Pharmaceuticals reports topline results from phase 3 shasta-3 and shasta-4 studies of plozasiran in patients with severe hypertriglyceridemia
Story updates
11:30:10 AM UTC
SquawkNews
ARWR Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
11:36:43 AM UTC
SquawkNews
ARWR - Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.